Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

The serum 25(OH)D was positively associated with age, and the serum 25(OH)D was significantly higher in postmenopausal women than that in pre/peri-menopausal women.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Full studies

Impact of serum vitamin D on the response and prognosis in breast cancer patients treated with neoadjuvant chemotherapy

Study design awaiting verification · Breast Cancer (Tokyo, Japan) · 2021

Original publication title

Impact of serum vitamin D on the response and prognosis in breast cancer patients treated with neoadjuvant chemotherapy

Eriko Tokunaga; Takanobu Masuda; Hideki Ijichi; Wakako Tajiri; Chinami Koga; Yumiko Koi; Yoshiaki Nakamura; Shinji Ohno; Kenichi Taguchi; Masahiro Okamoto

© The Author(s) 2021

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

The low 25(OH)D levels were significantly associated with poorer prognosis in Japanese women with operable breast cancer patients treated with NAC.

An extract from the source publication. Read it in context.

At a glance

Study background

What background does the paper provide?

Vitamin D is a fat-soluble secosteroid with well-established effects on calcium homeostasis, and it is the precursor to the potent steroid hormone calcitriol [1, 2]. Deficiency of vitamin D is associated with increased risks of morbidity and mortality in various diseases including cardiovascular, malignant, and autoimmune diseases [2Not reported5]. Vitamin D regulates numerous cellular pathways such as inhibition of cellular proliferation, inflammation, invasion, metastasis and angiogenesis, and also promotion of apoptosis and differentiation [2].

One of those mechanisms is the intervention on the cell cycle via kinases such as cyclins, cyclin-dependent kinases (CDKs) and CDK physiological modulators [6]. Previous studies have revealed that the vitamin D deficiency was associated with poor outcomes in breast cancer [7Not reported9], although contradictory results have also been reported [10, 11].

25-hydroxvitamin D (25(OH)D) is the circulating form of vitamin D that is measured in the blood and clinically used to establish and monitor the vitamin D status. One study showed that the serum 25(OH)D levels could predict cancer survival in a prospective cohort with measurements prior to and at the time of cancer diagnosis [12].

Neoadjuvant chemotherapy (NAC) has become a standard of care not only in locally advanced breast cancer, but in early breast cancer, especially for patients with large tumor size, lymph node metastasis, HER2 overexpression and triple negative breast cancer (TNBC) subtype. Pathological complete response (pCR) is associated with improved prognosis. This association appears stronger in the HER2+ /hormone receptor (HR): or TNBC subtype [13, 14].

Recently, a statistically significant association between 25(OH)D level at baseline and pCR in patients with receiving NAC has been reported [15, 16]. However, other studies reported that there was no effect of serum 25(OH)D levels on the pathologic complete response (pCR) in neoadjuvant settings [17Not reported19].

Recent reports shows that East Asian countries have high prevalence rates of Vit D deficiency [20, 21]. However, in Japan, the importance of the vitamin D on the incidence of cancer or the prognosis of the patients with malignancies has not been recognized so much. There are few studies on the association between serum vitamin D levels and the clinicopathological features and the prognosis of the Japanese women with breast cancer. In the present study, we retrospectively compared serum 25(OH)D level at baseline and the efficacy of NAC and the prognosis after surgery.

Source: Introduction Source: Introduction Source: Introduction Source: Introduction Source: Introduction

Study methods

What methods does the paper describe?

Patient population

A total of 250 patients with clinical Stage I: III primary breast cancer who were treated with NAC and subsequently underwent definitive surgery of the breast and axilla in the Department of Breast Oncology, National Hospital Organization Kyushu Cancer Center, between 2009 and 2019 were included in this study. Chemotherapy was administered according to the standard regimens of anthracyclines and/or taxanes with or without trastuzumab for HER2-positive (HER2+) breast cancer. For all these patients, serum obtained just before starting NAC was available.

The clinical data were obtained from the patients’ medical records. The anatomical AJCC/UICC TNM classification and stage groupings were used. This study was approved by the institutional review board of our hospital, and was in accordance with the Declaration of Helsinki. The serum was the surplus sample from the usual blood test. We obtained the written informed general consent from an individual patient before the start of the treatment and the sample acquisition. Our IRB waived the requirement for obtaining another written informed consent when we use the surplus samples.

Pathological examinations

All pathological examinations were performed by the experienced pathologists in our hospital. The expression of estrogen receptor (ER) and progesterone receptor (PgR) was regarded as positive if the nuclear expression was ≥ 1%. The HER2 status was evaluated according to the recommendation of ASCO/CAP [22]. The pCR was regarded as the total disappearance of invasive carcinoma cells, including lymph nodes, regardless of the presence of residual ductal carcinoma in situ. If ER and /or PgR were positive, it was defined HR-positive (HR+).

The tumor subtypes were divided into the following four groups; HR+ /HER2−, HR+ /HER2+ , HR−/HER2+ and triple negative (TN; ER−, PgR− and HER2−).

Serum vitamin D (25-hydroxyvitamin D; 25(OH)D) levels

Serum samples obtained before the first cycle of NAC were stored at − 30 °C until analysis. Serum 25(OH)D levels were analyzed by ELISA at SRL laboratories (Tokyo, Japan). Serum 25(OH)D levels were defined as ‘sufficient’ if serum 25(OH)D ≥ 20 ng/mL and ‘insufficient’ if serum 25(OH)D < 20 ng/mL [2, 19].

Statistical analyses

The statistical analyses were performed using the JMP software package, version 14.0 (SAS Institute Inc., Cary, NC, USA). The associations between the clinicopathological characteristics were assessed using χ2 tests. The time to recurrence (TTR) was defined as the time from surgery to the first breast cancer event, including loco-regional recurrence, distant metastasis or a new cancer in the contralateral breast. The time to distant recurrence (TTDR) was defined as the time from the date of curative surgery to the detection of distant recurrence.

The overall survival (OS) was defined as the time from the date of curative surgery to death. Survival curves were plotted using the Kaplan: Meier method, and the association between the survival and each variable was determined by the log-rank test. For multivariate analysis of the survival data, Cox proportional hazards model was used. Differences were considered to be significant at P < 0.05.

Source: Patients and methods Source: Patients and methods Source: Patients and methods Source: Patients and methods

Results: Patients’ characteristics

The clinicopathological characteristics of the patients included in this study were shown in Table 1. The median age was 59 years (range 28 to 75). Pre/peri-menopausal and postmenopausal women were 135 (54.0%) and 115 (46.0%), respectively. About 60% of the patients were at clinical stage II. The rate of ER, PgR and HER2-positivity was 69.6%, 48.0% and 39.2%, respectively. In terms of tumor subtypes, HR+ /HER2− were 111 (44.4%), HR+ /HER2+ 67 (26.8%), HR−/HER2+ 31 (12.4%) and TN 41 (16.4%), respectively.

Among the 250 patients, pCR was achieved in 60 (24.0%) patients.

Table 1

Clinicopathological characteristics of the patients

FactorsN (%)
Age (years)
 Median (range)59 (28 to 75)
Menopausal status
 Pre/perimenopause135 (54.0)
 Postmenopause115 (46.0)
Clinical stage
 I6 (2.4)
 IIA73 (29.2)
 IIB89 (35.6)
 IIIA21 (8.4)
 IIIB24 (9.6)
 IIIC37 (14.8)
Nuclear grade
 1, 2185 (74.6)
 363 (25.4)
ER
 Negative76 (30.4)
 Positive174 (69.6)
PgR
 Negative130 (52.0)
 Positive120 (48.0)
HER2
 Negative152 (60.8)
 Positive98 (39.2)
Subtype
 HR+/HER2−111 (44.4)
 HR+/HER2+ 67 (26.8)
 HR−/HER2+ 31 (12.4)
 TN41 (16.4)
Pathological efficacy
 pCR60 (24.0)
 Non-pCR190 (76.0)
25(OH)D
 Insufficient (< 20 ng/mL)241 (96.4)
 Sufficient (≥ 20 ng/mL)9 (3.6)

ER: estrogen receptor, PgR: progesterone receptor, pCR: pathological complete response, HR: hormone receptor, TN: triple-negative, 25(OH)D: 25-hydroxyvitamin D

Source: Patients’ characteristics

Relationships between the serum 25(OH)D level and the clinicopathological characteristics

Results: Relationships between the serum 25(OH)D level and the clinicopathological characteristics

The median 25(OH)D levels were 10.7 ng/mL (range 3.0 to 26.6 ng/mL). Surprisingly, serum 25(OH)D was sufficient in only nine patients (3.6%) in this cohort (Table 1). Serum 25(OH)D was positively associated with age (P = 0.0016), and serum 25(OH)D was significantly higher in postmenopausal women than that in pre/peri-menopausal women (P = 0.0020, Fig. 1). In the present study, serum 25(OH)D level was divided into two groups, low and high, using a dichotomous variable at the median value 10.7 ng/mL.

Relationships between the serum 25(OH)D level and the clinicopathological characteristics were shown in Table 2. The median age of the high 25(OH)D group was significantly higher than that of the low 25(OH)D group (52.7 ± 0.93 year old vs. 48.5 ± 0.93, P = 0.0015), and the number of the postmenopausal women was significantly higher in the high 25(OH)D group (P = 0.0022). There were no significant associations between serum 25(OH)D level and the clinical stage, ER and PgR expressions, HER2 status and tumor subtypes.

Fig. 1

Relationship between age and menopausal status and the serum 25(OH)D level. A Relationship between age and the serum 25(OH)D level. B Relationship between menopausal status and the 25(OH)D level

Figure image at the original source: open the original paper. This file is not included in this text import.

Table 2

Relationships between the clinicopathological characteristics and the serum 25(OH)D level

Factors25(OH)D low (n = 124)25(OH)D high (n = 126)P value
Age (years)
 Mean ± SE48.5 ± 0.9352.7 ± 0.930.0015
Menopausal status
 Pre/perimenopause79 (63.7)56 (44.4)0.0022
 Postmenopause45 (36.3)70 (55.6)
Clinical stage
 I2 (1.6)4 (3.2)0.147
 IIA35 (28.3)38 (30.2)
 IIB40 (32.3)49 (38.9)
 IIIA10 (8.1)11 (8.7)
 IIIB11 (8.9)13 (10.3)
 IIIC26 (21.0)11 (8.7)
Nuclear grade
 1, 285 (69.7)100 (79.4)0.0791
 337 (30.3)26 (20.6)
ER
 Negative36 (29.0)40 (31.8)0.6409
 Positive88 (71.0)86 (68.2)
PgR
 Negative64 (51.6)66 (52.4)0.9033
 Positive60 (48.4)60 (47.6)
HER2
 Negative75 (60.5)77 (61.1)0.9191
 Positive49 (39.5)49 (38.9)
Subtypes
 HR+/HER2−55 (44.4)56 (44.4)0.9313
 HR+/HER2+ 35 (28.2)32 (25.4)
 HR−/HER2+ 14 (11.3)17 813.9)
 TN20 (16.1)21 (16.7)

SE standard error, ER estrogen receptor, PgR progesterone receptor, HR hormone receptor, TN triple-negative, 25(OH)D 25-hydroxyvitamin D

Table 1

Clinicopathological characteristics of the patients

FactorsN (%)
Age (years)
 Median (range)59 (28 to 75)
Menopausal status
 Pre/perimenopause135 (54.0)
 Postmenopause115 (46.0)
Clinical stage
 I6 (2.4)
 IIA73 (29.2)
 IIB89 (35.6)
 IIIA21 (8.4)
 IIIB24 (9.6)
 IIIC37 (14.8)
Nuclear grade
 1, 2185 (74.6)
 363 (25.4)
ER
 Negative76 (30.4)
 Positive174 (69.6)
PgR
 Negative130 (52.0)
 Positive120 (48.0)
HER2
 Negative152 (60.8)
 Positive98 (39.2)
Subtype
 HR+/HER2−111 (44.4)
 HR+/HER2+ 67 (26.8)
 HR−/HER2+ 31 (12.4)
 TN41 (16.4)
Pathological efficacy
 pCR60 (24.0)
 Non-pCR190 (76.0)
25(OH)D
 Insufficient (< 20 ng/mL)241 (96.4)
 Sufficient (≥ 20 ng/mL)9 (3.6)

ER: estrogen receptor, PgR: progesterone receptor, pCR: pathological complete response, HR: hormone receptor, TN: triple-negative, 25(OH)D: 25-hydroxyvitamin D

Source: Relationships between the serum 25(OH)D level and the clinicopathological characteristics Source: Relationships between the serum 25(OH)D level and the clinicopathological characteristics

Relationships between serum 25(OH)D level and the efficacy of NAC

Results: Relationships between serum 25(OH)D level and the efficacy of NAC

Then, the relationships between the clinicopathological factors and the efficacy of NAC were analyzed (Table 3). The low clinical stage (I and II), PgR negativity (P < 0.0001) and HER2 positivity (P < 0.0001) were significantly associated with the higher achievement of pCR. The HR+ /HER2− subtype was associated with the lower achievement of pCR (P < 0.0001). However, there was no significant association between the serum 25(OH)D level and the pCR.

Table 3

Relationships between the clinicopathological factors and pCR

Non-pCR (n = 190)pCR (n = 60)P value
Menopausal status
 Pre/peri104 (54.7)31 (51.7)0.6776
 Post86 (45.3)29 (48.3)
Clinical stage
 I, II119 (62.6)49 (81.7)0.0045
 III71 (37.8)11 (18.3)
ER
 Negative52 (27.4)24 (40.0)0.0681
 Positive138 (72.6)36 (60.0)
PgR
 Negative83 (43.7)47 (78.3)< 0.0001
 Positive107 (56.3)13 (21.7)
HER2
 Negative131 (69.0)21 (35.0)< 0.0001
 Positive59 (31.0)39 (65.0)
Subtype
 HR+/HER2−100 (52.6)11 (18.3)< 0.0001
 HR+/HER2+ 42 (22.1)25 (41.7)
 HR−/HER2+ 17 (8.9)14 (23.3)
 TN31 (16.3)10 (16.7)
25(OH)D
 Low97 (51.0)27 (45.0)0.4133
 High93 (49.0)33 (55.0)

ER estrogen receptor, PgR progesterone receptor, pCR pathological complete response, HR hormone receptor, TN triple-negative, 25(OH)D 25-hydroxyvitamin D

Source: Relationships between serum 25(OH)D level and the efficacy of NAC

Relationships between serum 25(OH)D level and the prognosis

Results: Relationships between serum 25(OH)D level and the prognosis

Then, the relationships between serum 25(OH)D levels and the prognosis were evaluated. In spite of no associations with the efficacy of NAC, the prognosis of the patients with the low serum 25(OH)D level was associated with poorer prognosis. The TTDR was significantly shorter in the patients with low 25(OH)D level (P = 0.0179), and the TTR and OS was poorer in the patients with low 25(OH)D level, although not statistically significant (Fig. 2).

Fig. 2

Relationship between the serum 25(OH)D level and the prognosis. A Time to recurrence, B time to distant recurrence, C overall survival. Red line: 25(OH)D low (n = 124), blue line: 25(OH)D high (n = 126)

Figure image at the original source: open the original paper. This file is not included in this text import.

Source: Relationships between serum 25(OH)D level and the prognosis

Univariate and multivariate analyses of factors associated with TTDR

Results: Univariate and multivariate analyses of factors associated with TTDR

The clinicopathological factors possibly related to TTDR were analyzed by univariate and multivariate analyses (Table 4). According to the univariate analysis, high clinical stage before NAC (cStage III, P = 0.0165) and low serum 25(OH)D level (P = 0.0165) were significantly associated with the shorter TTDR, and pCR was significantly associated with the longer TTDR (P = 0.037). According to a multivariate analysis that included these factors, high clinical stage (cStage III) and low serum 25(OH)D level were independent poor prognostic factors for TTDR (P = 0.0445 and P = 0.0231, Table 4).

Table 4

Results of univariate and multivariate analyses for the TTDR

FactorsParametersUnivariate analysisMultivariate analysis
HR95% CIP valueHR95% CIP-value
Menopausal statusPre/peri vs. post0.940.47 to 1.900.8673
Clinical stage before NACIII vs. I, II2.341.17 to 4.670.01652.051.01 to 4.100.0445
ERPositive vs. negative1.090.53 to 2.410.811
PgRPositive vs. negative1.050.53 to 2.090.8842
HER2Positive vs. negative0.6010.26 to 1.250.1799
Tumor subtypesHER2, TN vs. HR+ /HER2−0.570.28 to 1.120.1043
Pathological efficacypCR vs. non-pCR0.340.08 to 0.940.0370.390.09 to 1.130.087
25(OH)DLow vs. high2.381.17 to 5.250.01652.281.12 to 5.030.0231

HR hazard ratio, CI confidence interval, TTDR time to distant recurrence, pCR pathological complete response, ER estrogen receptor, PgR progesterone receptor, HR hormone receptor, TN triple-negative, 25(OH)D 25-hydroxyvitamin D

Source: Univariate and multivariate analyses of factors associated with TTDR

Discussion

In the present study, we examined the relationships between the serum vitamin D (25(OH)D) levels and the pathological responses to NAC and the subsequent prognosis in Japanese women with operable breast cancer. There were no significant associations between the serum 25(OH)D levels and the pCR rate after NAC, however, the low serum 25(OH)D was significantly associated with the poor prognosis. As far as we know, this is the first study that investigated the association between the serum 25(OH)D levels and the efficacy of the NAC and the prognosis in the Japanese patients with breast cancer.

The association between vitamin D deficiency and the breast cancer risk and outcomes have been rigorously studied in Western countries, however, the data on the Asian women are lacking. For Japanese women, there is the only one case: control study using self-reported vitamin D intake, not serum 25(OD)D levels, which showed the significant inverse association with breast cancer [23]. In Korea, a large case: control study revealed that the deficient level of serum 25(OH)D was significantly associated with the breast cancer risk regardless of other breast cancer risk factors [24].

From these studies, vitamin D deficiency might be associated with the breast cancer risk in also Asian women.

In the Western countries, because there are lots of reports that showed the association between the vitamin D deficiency and the poor outcomes of breast cancer, the importance to intake sufficient vitamin D seems to have been recognized from an earlier time [7Not reported9, 12]. In a study from Canada, women with early-stage breast cancer diagnosed prior to 2005 frequently had low levels of vitamin D, however, women diagnosed in 2008 to 2009, vitamin D levels were higher, probably because of the use of vitamin D supplements [9] Although there are few data of Asian breast cancer patients, a very recent study from Thailand showed that low serum 25(OH)D level was found to be independently associated with poor survival in breast cancer patients, regardless of age, lymph node status, stage or breast cancer subtype [25].

The associations between the serum 25(OH)D levels and the pathological responses to NAC were inconsistent among studies. In the reports by Chiba et al. and Viala et al. from the same group, a significant association between the serum 25(OH)D levels and the pathological responses to NAC (pCR) was recognized [15, 16]. On the other hand, in the patients enrolled in NEOZOTAC phase III trial or the study conducted in Korea, baseline and end of NAC 25(OH)D levels and the changes of the 25(OH)D levels were not related to the pathological responses [17, 19].

The rate of the patients with sufficient 25(OH) D levels are different among studies. More than 60% of the patients were at the sufficient level in the study by Chiba et al. and Viala et al. and NEOZOTAC trial. However, 25(OH) D were at sufficient level in only 16.8% in the study of Kim et al. In NEOZOTAC trial, only patients with HER2− breast cancer were included and other studies included the patients with both HER2− and HER2+ patients. In addition, pCR rate was different among studies.

These factors might have influences on these inconsistencies.

In the present study, the low 25(OH)D was significantly associated with the poor prognosis and it was an independent poor prognostic factor by the multivariate analysis.

Surprisingly, serum 25(OH)D levels in most patients were insufficient (< 20 ng/mL) in our cohort. Serum 25(OH)D was positively associated with age, and serum 25(OH)D was significantly higher in postmenopausal women than that in pre/peri-menopausal women. Because the vitamin D deficiency is associated with the breast carcinogenesis, and the subjects of this study were all breast cancer patients, the vitamin D levels might have been lower than that of the healthy Japanese women. The low 25(OH)D levels in the breast cancer patients were also recognized in other studies of the Asian women [19, 24, 25].

In the Korean study of NAC, the median 25(OH)D levels were also significantly lower than that of the women in the Western countries, and the sufficient levels were more often observed in postmenopausal women, which are similar to our results [19]. Only two postmenopausal patients received an analogue of 1,25-dihydroxyvitamin D3 [1,25(OH)2D3]. The intake of these active vitamin D3 analog does not change the serum 25(OH)D level. Therefore, we think that the intake of active vitamin D3 analog had no effects of the result of this study.

As a consequence of indoor occupations and reduced exposure to sunlight, concerns for the vitamin D deficiency have been raised in developed countries [3, 4]. Also in Japan, females appear to be at higher risk of vitamin D deficiency because the younger people consume less fish than elders, they tend to avoid direct sunlight exposure to prevent skin-tanning, and they may be malnourished from maintaining a lean proportion [26Not reported30]. We showed here the relationship between the low vitamin D and the poor prognosis in the Japanese women with primary breast cancer for the first time.

We have not given the sufficient attention to the vitamin D in terms of the breast cancer risk and the prognosis in Japan. In addition, the analysis of 25(OH)D is not approved by the medical insurance in the ordinary practice of breast cancer in Japan. Therefore, the research regarding this theme might have not been done much in our country. We should pay more attention to vitamin D in regard to the cancer prevention and the prognosis.

The strength of the present study is that these data are form a single institution with high-quality follow-up and updated clinical data. However, these are several limitations associated with our study as well. All data are retrospective, and the duration of the follow-up was not sufficient. The number of the patients included in this study was small. In the present study, we included the only patients who underwent surgery after NAC. The cut-off value of the serum 25(OH)D was different from those in previous studies, most of which adopted 20 ng/mL as the cut off.

To elucidate the association between serum vitamin D and the outcome of the breast cancer, the study using the large cohort which include the patients with or without NAC is necessary.

In conclusion, serum vitamin D level at the baseline was not associated with pCR rate after NAC, however, low serum vitamin D level was significantly associated with the poor prognosis in Japanese women. Vitamin D is important not only for the bone metabolism, but also in the cancer risk and prognosis. Therefore, we should pay more attention to the vitamin D intake. It is a great interest that the supplement of vitamin D could improve the prognosis of the breast cancer patients.

Source: Discussion Source: Discussion Source: Discussion Source: Discussion Source: Discussion Source: Discussion Source: Discussion Source: Discussion Source: Discussion

Results

Patients’ characteristics

The clinicopathological characteristics of the patients included in this study were shown in Table 1. The median age was 59 years (range 28 to 75). Pre/peri-menopausal and postmenopausal women were 135 (54.0%) and 115 (46.0%), respectively. About 60% of the patients were at clinical stage II. The rate of ER, PgR and HER2-positivity was 69.6%, 48.0% and 39.2%, respectively. In terms of tumor subtypes, HR+ /HER2− were 111 (44.4%), HR+ /HER2+ 67 (26.8%), HR−/HER2+ 31 (12.4%) and TN 41 (16.4%), respectively.

Among the 250 patients, pCR was achieved in 60 (24.0%) patients.

Table 1

Clinicopathological characteristics of the patients

FactorsN (%)
Age (years)
 Median (range)59 (28 to 75)
Menopausal status
 Pre/perimenopause135 (54.0)
 Postmenopause115 (46.0)
Clinical stage
 I6 (2.4)
 IIA73 (29.2)
 IIB89 (35.6)
 IIIA21 (8.4)
 IIIB24 (9.6)
 IIIC37 (14.8)
Nuclear grade
 1, 2185 (74.6)
 363 (25.4)
ER
 Negative76 (30.4)
 Positive174 (69.6)
PgR
 Negative130 (52.0)
 Positive120 (48.0)
HER2
 Negative152 (60.8)
 Positive98 (39.2)
Subtype
 HR+/HER2−111 (44.4)
 HR+/HER2+ 67 (26.8)
 HR−/HER2+ 31 (12.4)
 TN41 (16.4)
Pathological efficacy
 pCR60 (24.0)
 Non-pCR190 (76.0)
25(OH)D
 Insufficient (< 20 ng/mL)241 (96.4)
 Sufficient (≥ 20 ng/mL)9 (3.6)

ER: estrogen receptor, PgR: progesterone receptor, pCR: pathological complete response, HR: hormone receptor, TN: triple-negative, 25(OH)D: 25-hydroxyvitamin D

Relationships between the serum 25(OH)D level and the clinicopathological characteristics

The median 25(OH)D levels were 10.7 ng/mL (range 3.0 to 26.6 ng/mL). Surprisingly, serum 25(OH)D was sufficient in only nine patients (3.6%) in this cohort (Table 1). Serum 25(OH)D was positively associated with age (P = 0.0016), and serum 25(OH)D was significantly higher in postmenopausal women than that in pre/peri-menopausal women (P = 0.0020, Fig. 1). In the present study, serum 25(OH)D level was divided into two groups, low and high, using a dichotomous variable at the median value 10.7 ng/mL.

Relationships between the serum 25(OH)D level and the clinicopathological characteristics were shown in Table 2. The median age of the high 25(OH)D group was significantly higher than that of the low 25(OH)D group (52.7 ± 0.93 year old vs. 48.5 ± 0.93, P = 0.0015), and the number of the postmenopausal women was significantly higher in the high 25(OH)D group (P = 0.0022). There were no significant associations between serum 25(OH)D level and the clinical stage, ER and PgR expressions, HER2 status and tumor subtypes.

Fig. 1

Relationship between age and menopausal status and the serum 25(OH)D level. A Relationship between age and the serum 25(OH)D level. B Relationship between menopausal status and the 25(OH)D level

Figure image at the original source: open the original paper. This file is not included in this text import.

Table 2

Relationships between the clinicopathological characteristics and the serum 25(OH)D level

Factors25(OH)D low (n = 124)25(OH)D high (n = 126)P value
Age (years)
 Mean ± SE48.5 ± 0.9352.7 ± 0.930.0015
Menopausal status
 Pre/perimenopause79 (63.7)56 (44.4)0.0022
 Postmenopause45 (36.3)70 (55.6)
Clinical stage
 I2 (1.6)4 (3.2)0.147
 IIA35 (28.3)38 (30.2)
 IIB40 (32.3)49 (38.9)
 IIIA10 (8.1)11 (8.7)
 IIIB11 (8.9)13 (10.3)
 IIIC26 (21.0)11 (8.7)
Nuclear grade
 1, 285 (69.7)100 (79.4)0.0791
 337 (30.3)26 (20.6)
ER
 Negative36 (29.0)40 (31.8)0.6409
 Positive88 (71.0)86 (68.2)
PgR
 Negative64 (51.6)66 (52.4)0.9033
 Positive60 (48.4)60 (47.6)
HER2
 Negative75 (60.5)77 (61.1)0.9191
 Positive49 (39.5)49 (38.9)
Subtypes
 HR+/HER2−55 (44.4)56 (44.4)0.9313
 HR+/HER2+ 35 (28.2)32 (25.4)
 HR−/HER2+ 14 (11.3)17 813.9)
 TN20 (16.1)21 (16.7)

SE standard error, ER estrogen receptor, PgR progesterone receptor, HR hormone receptor, TN triple-negative, 25(OH)D 25-hydroxyvitamin D

Relationships between serum 25(OH)D level and the efficacy of NAC

Then, the relationships between the clinicopathological factors and the efficacy of NAC were analyzed (Table 3). The low clinical stage (I and II), PgR negativity (P < 0.0001) and HER2 positivity (P < 0.0001) were significantly associated with the higher achievement of pCR. The HR+ /HER2− subtype was associated with the lower achievement of pCR (P < 0.0001). However, there was no significant association between the serum 25(OH)D level and the pCR.

Table 3

Relationships between the clinicopathological factors and pCR

Non-pCR (n = 190)pCR (n = 60)P value
Menopausal status
 Pre/peri104 (54.7)31 (51.7)0.6776
 Post86 (45.3)29 (48.3)
Clinical stage
 I, II119 (62.6)49 (81.7)0.0045
 III71 (37.8)11 (18.3)
ER
 Negative52 (27.4)24 (40.0)0.0681
 Positive138 (72.6)36 (60.0)
PgR
 Negative83 (43.7)47 (78.3)< 0.0001
 Positive107 (56.3)13 (21.7)
HER2
 Negative131 (69.0)21 (35.0)< 0.0001
 Positive59 (31.0)39 (65.0)
Subtype
 HR+/HER2−100 (52.6)11 (18.3)< 0.0001
 HR+/HER2+ 42 (22.1)25 (41.7)
 HR−/HER2+ 17 (8.9)14 (23.3)
 TN31 (16.3)10 (16.7)
25(OH)D
 Low97 (51.0)27 (45.0)0.4133
 High93 (49.0)33 (55.0)

ER estrogen receptor, PgR progesterone receptor, pCR pathological complete response, HR hormone receptor, TN triple-negative, 25(OH)D 25-hydroxyvitamin D

Relationships between serum 25(OH)D level and the prognosis

Then, the relationships between serum 25(OH)D levels and the prognosis were evaluated. In spite of no associations with the efficacy of NAC, the prognosis of the patients with the low serum 25(OH)D level was associated with poorer prognosis. The TTDR was significantly shorter in the patients with low 25(OH)D level (P = 0.0179), and the TTR and OS was poorer in the patients with low 25(OH)D level, although not statistically significant (Fig. 2).

Fig. 2

Relationship between the serum 25(OH)D level and the prognosis. A Time to recurrence, B time to distant recurrence, C overall survival. Red line: 25(OH)D low (n = 124), blue line: 25(OH)D high (n = 126)

Figure image at the original source: open the original paper. This file is not included in this text import.

Univariate and multivariate analyses of factors associated with TTDR

The clinicopathological factors possibly related to TTDR were analyzed by univariate and multivariate analyses (Table 4). According to the univariate analysis, high clinical stage before NAC (cStage III, P = 0.0165) and low serum 25(OH)D level (P = 0.0165) were significantly associated with the shorter TTDR, and pCR was significantly associated with the longer TTDR (P = 0.037). According to a multivariate analysis that included these factors, high clinical stage (cStage III) and low serum 25(OH)D level were independent poor prognostic factors for TTDR (P = 0.0445 and P = 0.0231, Table 4).

Table 4

Results of univariate and multivariate analyses for the TTDR

FactorsParametersUnivariate analysisMultivariate analysis
HR95% CIP valueHR95% CIP-value
Menopausal statusPre/peri vs. post0.940.47 to 1.900.8673
Clinical stage before NACIII vs. I, II2.341.17 to 4.670.01652.051.01 to 4.100.0445
ERPositive vs. negative1.090.53 to 2.410.811
PgRPositive vs. negative1.050.53 to 2.090.8842
HER2Positive vs. negative0.6010.26 to 1.250.1799
Tumor subtypesHER2, TN vs. HR+ /HER2−0.570.28 to 1.120.1043
Pathological efficacypCR vs. non-pCR0.340.08 to 0.940.0370.390.09 to 1.130.087
25(OH)DLow vs. high2.381.17 to 5.250.01652.281.12 to 5.030.0231

HR hazard ratio, CI confidence interval, TTDR time to distant recurrence, pCR pathological complete response, ER estrogen receptor, PgR progesterone receptor, HR hormone receptor, TN triple-negative, 25(OH)D 25-hydroxyvitamin D

Source: Results Source: Results Source: Results Source: Results Source: Results

Abstract: Conclusions

The low 25(OH)D levels were significantly associated with poorer prognosis in Japanese women with operable breast cancer patients treated with NAC.

Source: Conclusions
Authors’ abstract

Background

Several studies have recently reported that the relationships between serum vitamin D and the prognosis or the pathological response to neoadjuvant chemotherapy (NAC) in breast cancer. However, there are no data regarding the clinical impacts of the vitamin D in Japanese breast cancer patients so far.

Patients and methods

In the present study, a total of 250 patients with clinical Stage I: III primary breast cancer who were treated with NAC and subsequently underwent definitive surgery were included. Serum 25-hydroxvitamin D (25(OH)D) levels were evaluated using blood samples obtained before NAC.

Results

The serum 25(OH)D was positively associated with age, and the serum 25(OH)D was significantly higher in postmenopausal women than that in pre/peri-menopausal women. Serum 25(OH)D level was not associated with the achievement of pathological complete response (pCR) in this cohort. The low 25(OH)D levels were significantly associated with shorter time to distant recurrence (TTDR). According to the univariate analysis, high clinical stage before NAC (cStage III) and low serum 25(OH)D level were significantly associated with the shorter TTDR, and pCR was significantly associated with the longer TTDR.

According to a multivariate analysis, low serum 25(OH)D level were independent poor prognostic factors for TTDR.

Conclusions

The low 25(OH)D levels were significantly associated with poorer prognosis in Japanese women with operable breast cancer patients treated with NAC.

Read the full paper

Introduction

Vitamin D is a fat-soluble secosteroid with well-established effects on calcium homeostasis, and it is the precursor to the potent steroid hormone calcitriol [1, 2]. Deficiency of vitamin D is associated with increased risks of morbidity and mortality in various diseases including cardiovascular, malignant, and autoimmune diseases [2Not reported5]. Vitamin D regulates numerous cellular pathways such as inhibition of cellular proliferation, inflammation, invasion, metastasis and angiogenesis, and also promotion of apoptosis and differentiation [2].

One of those mechanisms is the intervention on the cell cycle via kinases such as cyclins, cyclin-dependent kinases (CDKs) and CDK physiological modulators [6]. Previous studies have revealed that the vitamin D deficiency was associated with poor outcomes in breast cancer [7Not reported9], although contradictory results have also been reported [10, 11].

25-hydroxvitamin D (25(OH)D) is the circulating form of vitamin D that is measured in the blood and clinically used to establish and monitor the vitamin D status. One study showed that the serum 25(OH)D levels could predict cancer survival in a prospective cohort with measurements prior to and at the time of cancer diagnosis [12].

Neoadjuvant chemotherapy (NAC) has become a standard of care not only in locally advanced breast cancer, but in early breast cancer, especially for patients with large tumor size, lymph node metastasis, HER2 overexpression and triple negative breast cancer (TNBC) subtype. Pathological complete response (pCR) is associated with improved prognosis. This association appears stronger in the HER2+ /hormone receptor (HR): or TNBC subtype [13, 14].

Recently, a statistically significant association between 25(OH)D level at baseline and pCR in patients with receiving NAC has been reported [15, 16]. However, other studies reported that there was no effect of serum 25(OH)D levels on the pathologic complete response (pCR) in neoadjuvant settings [17Not reported19].

Recent reports shows that East Asian countries have high prevalence rates of Vit D deficiency [20, 21]. However, in Japan, the importance of the vitamin D on the incidence of cancer or the prognosis of the patients with malignancies has not been recognized so much. There are few studies on the association between serum vitamin D levels and the clinicopathological features and the prognosis of the Japanese women with breast cancer. In the present study, we retrospectively compared serum 25(OH)D level at baseline and the efficacy of NAC and the prognosis after surgery.

Patients and methods

Patient population

A total of 250 patients with clinical Stage I: III primary breast cancer who were treated with NAC and subsequently underwent definitive surgery of the breast and axilla in the Department of Breast Oncology, National Hospital Organization Kyushu Cancer Center, between 2009 and 2019 were included in this study. Chemotherapy was administered according to the standard regimens of anthracyclines and/or taxanes with or without trastuzumab for HER2-positive (HER2+) breast cancer. For all these patients, serum obtained just before starting NAC was available.

The clinical data were obtained from the patients’ medical records. The anatomical AJCC/UICC TNM classification and stage groupings were used. This study was approved by the institutional review board of our hospital, and was in accordance with the Declaration of Helsinki. The serum was the surplus sample from the usual blood test. We obtained the written informed general consent from an individual patient before the start of the treatment and the sample acquisition. Our IRB waived the requirement for obtaining another written informed consent when we use the surplus samples.

Pathological examinations

All pathological examinations were performed by the experienced pathologists in our hospital. The expression of estrogen receptor (ER) and progesterone receptor (PgR) was regarded as positive if the nuclear expression was ≥ 1%. The HER2 status was evaluated according to the recommendation of ASCO/CAP [22]. The pCR was regarded as the total disappearance of invasive carcinoma cells, including lymph nodes, regardless of the presence of residual ductal carcinoma in situ. If ER and /or PgR were positive, it was defined HR-positive (HR+).

The tumor subtypes were divided into the following four groups; HR+ /HER2−, HR+ /HER2+ , HR−/HER2+ and triple negative (TN; ER−, PgR− and HER2−).

Serum vitamin D (25-hydroxyvitamin D; 25(OH)D) levels

Serum samples obtained before the first cycle of NAC were stored at − 30 °C until analysis. Serum 25(OH)D levels were analyzed by ELISA at SRL laboratories (Tokyo, Japan). Serum 25(OH)D levels were defined as ‘sufficient’ if serum 25(OH)D ≥ 20 ng/mL and ‘insufficient’ if serum 25(OH)D < 20 ng/mL [2, 19].

Statistical analyses

The statistical analyses were performed using the JMP software package, version 14.0 (SAS Institute Inc., Cary, NC, USA). The associations between the clinicopathological characteristics were assessed using χ2 tests. The time to recurrence (TTR) was defined as the time from surgery to the first breast cancer event, including loco-regional recurrence, distant metastasis or a new cancer in the contralateral breast. The time to distant recurrence (TTDR) was defined as the time from the date of curative surgery to the detection of distant recurrence.

The overall survival (OS) was defined as the time from the date of curative surgery to death. Survival curves were plotted using the Kaplan: Meier method, and the association between the survival and each variable was determined by the log-rank test. For multivariate analysis of the survival data, Cox proportional hazards model was used. Differences were considered to be significant at P < 0.05.

Results

Patients’ characteristics

The clinicopathological characteristics of the patients included in this study were shown in Table 1. The median age was 59 years (range 28 to 75). Pre/peri-menopausal and postmenopausal women were 135 (54.0%) and 115 (46.0%), respectively. About 60% of the patients were at clinical stage II. The rate of ER, PgR and HER2-positivity was 69.6%, 48.0% and 39.2%, respectively. In terms of tumor subtypes, HR+ /HER2− were 111 (44.4%), HR+ /HER2+ 67 (26.8%), HR−/HER2+ 31 (12.4%) and TN 41 (16.4%), respectively.

Among the 250 patients, pCR was achieved in 60 (24.0%) patients.

Table 1

Clinicopathological characteristics of the patients

FactorsN (%)
Age (years)
 Median (range)59 (28 to 75)
Menopausal status
 Pre/perimenopause135 (54.0)
 Postmenopause115 (46.0)
Clinical stage
 I6 (2.4)
 IIA73 (29.2)
 IIB89 (35.6)
 IIIA21 (8.4)
 IIIB24 (9.6)
 IIIC37 (14.8)
Nuclear grade
 1, 2185 (74.6)
 363 (25.4)
ER
 Negative76 (30.4)
 Positive174 (69.6)
PgR
 Negative130 (52.0)
 Positive120 (48.0)
HER2
 Negative152 (60.8)
 Positive98 (39.2)
Subtype
 HR+/HER2−111 (44.4)
 HR+/HER2+ 67 (26.8)
 HR−/HER2+ 31 (12.4)
 TN41 (16.4)
Pathological efficacy
 pCR60 (24.0)
 Non-pCR190 (76.0)
25(OH)D
 Insufficient (< 20 ng/mL)241 (96.4)
 Sufficient (≥ 20 ng/mL)9 (3.6)

ER: estrogen receptor, PgR: progesterone receptor, pCR: pathological complete response, HR: hormone receptor, TN: triple-negative, 25(OH)D: 25-hydroxyvitamin D

Relationships between the serum 25(OH)D level and the clinicopathological characteristics

The median 25(OH)D levels were 10.7 ng/mL (range 3.0 to 26.6 ng/mL). Surprisingly, serum 25(OH)D was sufficient in only nine patients (3.6%) in this cohort (Table 1). Serum 25(OH)D was positively associated with age (P = 0.0016), and serum 25(OH)D was significantly higher in postmenopausal women than that in pre/peri-menopausal women (P = 0.0020, Fig. 1). In the present study, serum 25(OH)D level was divided into two groups, low and high, using a dichotomous variable at the median value 10.7 ng/mL.

Relationships between the serum 25(OH)D level and the clinicopathological characteristics were shown in Table 2. The median age of the high 25(OH)D group was significantly higher than that of the low 25(OH)D group (52.7 ± 0.93 year old vs. 48.5 ± 0.93, P = 0.0015), and the number of the postmenopausal women was significantly higher in the high 25(OH)D group (P = 0.0022). There were no significant associations between serum 25(OH)D level and the clinical stage, ER and PgR expressions, HER2 status and tumor subtypes.

Fig. 1

Relationship between age and menopausal status and the serum 25(OH)D level. A Relationship between age and the serum 25(OH)D level. B Relationship between menopausal status and the 25(OH)D level

Figure image at the original source: open the original paper. This file is not included in this text import.

Table 2

Relationships between the clinicopathological characteristics and the serum 25(OH)D level

Factors25(OH)D low (n = 124)25(OH)D high (n = 126)P value
Age (years)
 Mean ± SE48.5 ± 0.9352.7 ± 0.930.0015
Menopausal status
 Pre/perimenopause79 (63.7)56 (44.4)0.0022
 Postmenopause45 (36.3)70 (55.6)
Clinical stage
 I2 (1.6)4 (3.2)0.147
 IIA35 (28.3)38 (30.2)
 IIB40 (32.3)49 (38.9)
 IIIA10 (8.1)11 (8.7)
 IIIB11 (8.9)13 (10.3)
 IIIC26 (21.0)11 (8.7)
Nuclear grade
 1, 285 (69.7)100 (79.4)0.0791
 337 (30.3)26 (20.6)
ER
 Negative36 (29.0)40 (31.8)0.6409
 Positive88 (71.0)86 (68.2)
PgR
 Negative64 (51.6)66 (52.4)0.9033
 Positive60 (48.4)60 (47.6)
HER2
 Negative75 (60.5)77 (61.1)0.9191
 Positive49 (39.5)49 (38.9)
Subtypes
 HR+/HER2−55 (44.4)56 (44.4)0.9313
 HR+/HER2+ 35 (28.2)32 (25.4)
 HR−/HER2+ 14 (11.3)17 813.9)
 TN20 (16.1)21 (16.7)

SE standard error, ER estrogen receptor, PgR progesterone receptor, HR hormone receptor, TN triple-negative, 25(OH)D 25-hydroxyvitamin D

Relationships between serum 25(OH)D level and the efficacy of NAC

Then, the relationships between the clinicopathological factors and the efficacy of NAC were analyzed (Table 3). The low clinical stage (I and II), PgR negativity (P < 0.0001) and HER2 positivity (P < 0.0001) were significantly associated with the higher achievement of pCR. The HR+ /HER2− subtype was associated with the lower achievement of pCR (P < 0.0001). However, there was no significant association between the serum 25(OH)D level and the pCR.

Table 3

Relationships between the clinicopathological factors and pCR

Non-pCR (n = 190)pCR (n = 60)P value
Menopausal status
 Pre/peri104 (54.7)31 (51.7)0.6776
 Post86 (45.3)29 (48.3)
Clinical stage
 I, II119 (62.6)49 (81.7)0.0045
 III71 (37.8)11 (18.3)
ER
 Negative52 (27.4)24 (40.0)0.0681
 Positive138 (72.6)36 (60.0)
PgR
 Negative83 (43.7)47 (78.3)< 0.0001
 Positive107 (56.3)13 (21.7)
HER2
 Negative131 (69.0)21 (35.0)< 0.0001
 Positive59 (31.0)39 (65.0)
Subtype
 HR+/HER2−100 (52.6)11 (18.3)< 0.0001
 HR+/HER2+ 42 (22.1)25 (41.7)
 HR−/HER2+ 17 (8.9)14 (23.3)
 TN31 (16.3)10 (16.7)
25(OH)D
 Low97 (51.0)27 (45.0)0.4133
 High93 (49.0)33 (55.0)

ER estrogen receptor, PgR progesterone receptor, pCR pathological complete response, HR hormone receptor, TN triple-negative, 25(OH)D 25-hydroxyvitamin D

Relationships between serum 25(OH)D level and the prognosis

Then, the relationships between serum 25(OH)D levels and the prognosis were evaluated. In spite of no associations with the efficacy of NAC, the prognosis of the patients with the low serum 25(OH)D level was associated with poorer prognosis. The TTDR was significantly shorter in the patients with low 25(OH)D level (P = 0.0179), and the TTR and OS was poorer in the patients with low 25(OH)D level, although not statistically significant (Fig. 2).

Fig. 2

Relationship between the serum 25(OH)D level and the prognosis. A Time to recurrence, B time to distant recurrence, C overall survival. Red line: 25(OH)D low (n = 124), blue line: 25(OH)D high (n = 126)

Figure image at the original source: open the original paper. This file is not included in this text import.

Univariate and multivariate analyses of factors associated with TTDR

The clinicopathological factors possibly related to TTDR were analyzed by univariate and multivariate analyses (Table 4). According to the univariate analysis, high clinical stage before NAC (cStage III, P = 0.0165) and low serum 25(OH)D level (P = 0.0165) were significantly associated with the shorter TTDR, and pCR was significantly associated with the longer TTDR (P = 0.037). According to a multivariate analysis that included these factors, high clinical stage (cStage III) and low serum 25(OH)D level were independent poor prognostic factors for TTDR (P = 0.0445 and P = 0.0231, Table 4).

Table 4

Results of univariate and multivariate analyses for the TTDR

FactorsParametersUnivariate analysisMultivariate analysis
HR95% CIP valueHR95% CIP-value
Menopausal statusPre/peri vs. post0.940.47 to 1.900.8673
Clinical stage before NACIII vs. I, II2.341.17 to 4.670.01652.051.01 to 4.100.0445
ERPositive vs. negative1.090.53 to 2.410.811
PgRPositive vs. negative1.050.53 to 2.090.8842
HER2Positive vs. negative0.6010.26 to 1.250.1799
Tumor subtypesHER2, TN vs. HR+ /HER2−0.570.28 to 1.120.1043
Pathological efficacypCR vs. non-pCR0.340.08 to 0.940.0370.390.09 to 1.130.087
25(OH)DLow vs. high2.381.17 to 5.250.01652.281.12 to 5.030.0231

HR hazard ratio, CI confidence interval, TTDR time to distant recurrence, pCR pathological complete response, ER estrogen receptor, PgR progesterone receptor, HR hormone receptor, TN triple-negative, 25(OH)D 25-hydroxyvitamin D

Discussion

In the present study, we examined the relationships between the serum vitamin D (25(OH)D) levels and the pathological responses to NAC and the subsequent prognosis in Japanese women with operable breast cancer. There were no significant associations between the serum 25(OH)D levels and the pCR rate after NAC, however, the low serum 25(OH)D was significantly associated with the poor prognosis. As far as we know, this is the first study that investigated the association between the serum 25(OH)D levels and the efficacy of the NAC and the prognosis in the Japanese patients with breast cancer.

The association between vitamin D deficiency and the breast cancer risk and outcomes have been rigorously studied in Western countries, however, the data on the Asian women are lacking. For Japanese women, there is the only one case: control study using self-reported vitamin D intake, not serum 25(OD)D levels, which showed the significant inverse association with breast cancer [23]. In Korea, a large case: control study revealed that the deficient level of serum 25(OH)D was significantly associated with the breast cancer risk regardless of other breast cancer risk factors [24].

From these studies, vitamin D deficiency might be associated with the breast cancer risk in also Asian women.

In the Western countries, because there are lots of reports that showed the association between the vitamin D deficiency and the poor outcomes of breast cancer, the importance to intake sufficient vitamin D seems to have been recognized from an earlier time [7Not reported9, 12]. In a study from Canada, women with early-stage breast cancer diagnosed prior to 2005 frequently had low levels of vitamin D, however, women diagnosed in 2008 to 2009, vitamin D levels were higher, probably because of the use of vitamin D supplements [9] Although there are few data of Asian breast cancer patients, a very recent study from Thailand showed that low serum 25(OH)D level was found to be independently associated with poor survival in breast cancer patients, regardless of age, lymph node status, stage or breast cancer subtype [25].

The associations between the serum 25(OH)D levels and the pathological responses to NAC were inconsistent among studies. In the reports by Chiba et al. and Viala et al. from the same group, a significant association between the serum 25(OH)D levels and the pathological responses to NAC (pCR) was recognized [15, 16]. On the other hand, in the patients enrolled in NEOZOTAC phase III trial or the study conducted in Korea, baseline and end of NAC 25(OH)D levels and the changes of the 25(OH)D levels were not related to the pathological responses [17, 19].

The rate of the patients with sufficient 25(OH) D levels are different among studies. More than 60% of the patients were at the sufficient level in the study by Chiba et al. and Viala et al. and NEOZOTAC trial. However, 25(OH) D were at sufficient level in only 16.8% in the study of Kim et al. In NEOZOTAC trial, only patients with HER2− breast cancer were included and other studies included the patients with both HER2− and HER2+ patients. In addition, pCR rate was different among studies.

These factors might have influences on these inconsistencies.

In the present study, the low 25(OH)D was significantly associated with the poor prognosis and it was an independent poor prognostic factor by the multivariate analysis.

Surprisingly, serum 25(OH)D levels in most patients were insufficient (< 20 ng/mL) in our cohort. Serum 25(OH)D was positively associated with age, and serum 25(OH)D was significantly higher in postmenopausal women than that in pre/peri-menopausal women. Because the vitamin D deficiency is associated with the breast carcinogenesis, and the subjects of this study were all breast cancer patients, the vitamin D levels might have been lower than that of the healthy Japanese women. The low 25(OH)D levels in the breast cancer patients were also recognized in other studies of the Asian women [19, 24, 25].

In the Korean study of NAC, the median 25(OH)D levels were also significantly lower than that of the women in the Western countries, and the sufficient levels were more often observed in postmenopausal women, which are similar to our results [19]. Only two postmenopausal patients received an analogue of 1,25-dihydroxyvitamin D3 [1,25(OH)2D3]. The intake of these active vitamin D3 analog does not change the serum 25(OH)D level. Therefore, we think that the intake of active vitamin D3 analog had no effects of the result of this study.

As a consequence of indoor occupations and reduced exposure to sunlight, concerns for the vitamin D deficiency have been raised in developed countries [3, 4]. Also in Japan, females appear to be at higher risk of vitamin D deficiency because the younger people consume less fish than elders, they tend to avoid direct sunlight exposure to prevent skin-tanning, and they may be malnourished from maintaining a lean proportion [26Not reported30]. We showed here the relationship between the low vitamin D and the poor prognosis in the Japanese women with primary breast cancer for the first time.

We have not given the sufficient attention to the vitamin D in terms of the breast cancer risk and the prognosis in Japan. In addition, the analysis of 25(OH)D is not approved by the medical insurance in the ordinary practice of breast cancer in Japan. Therefore, the research regarding this theme might have not been done much in our country. We should pay more attention to vitamin D in regard to the cancer prevention and the prognosis.

The strength of the present study is that these data are form a single institution with high-quality follow-up and updated clinical data. However, these are several limitations associated with our study as well. All data are retrospective, and the duration of the follow-up was not sufficient. The number of the patients included in this study was small. In the present study, we included the only patients who underwent surgery after NAC. The cut-off value of the serum 25(OH)D was different from those in previous studies, most of which adopted 20 ng/mL as the cut off.

To elucidate the association between serum vitamin D and the outcome of the breast cancer, the study using the large cohort which include the patients with or without NAC is necessary.

In conclusion, serum vitamin D level at the baseline was not associated with pCR rate after NAC, however, low serum vitamin D level was significantly associated with the poor prognosis in Japanese women. Vitamin D is important not only for the bone metabolism, but also in the cancer risk and prognosis. Therefore, we should pay more attention to the vitamin D intake. It is a great interest that the supplement of vitamin D could improve the prognosis of the breast cancer patients.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Acknowledgements

We thank Ms. Kimiko Baba, Ms. Maki Tanaka and Ms. Yumiko Tatesaka for their valuable assistance.

Declarations

Conflict of interest

Eriko Tokunaga received lecture fee from Chugai, AstraZeneca and Eli Lilly. Other authors declare no conflict of interest.

References

1. Holick MF Chen TC Vitamin D deficiency: a worldwide problem with health consequences Am J Clin Nutr 2008 87 1080S S1086 10.1093/ajcn/87.4.1080S 18400738
2. Feldman D Krishnan AV Swami S Giovannucci E Feldman BJ The role of vitamin D in reducing cancer risk and progression Nat Rev Cancer 2014 14 342 357 10.1038/nrc3691 24705652
3. Baggerly CA Cuomo RE French CB Garland CF Gorham ED Grant WB Sunlight and vitamin D: necessary for public health J Am Coll Nutr 2015 34 359 365 10.1080/07315724.2015.1039866 26098394 PMC4536937
4. Holick MF Vitamin D deficiency N Engl J Med 2007 357 266 281 10.1056/NEJMra070553 17634462
5. Deeb KK Trump DL Johnson CS Vitamin D signalling pathways in cancer: potential for anticancer therapeutics Nat Rev Cancer 2007 7 684 700 10.1038/nrc2196 17721433
6. Verlinden L Verstuyf A Convents R Marcelis S Van Camp M Bouillon R Action of 1,25(OH)2D3 on the cell cycle genes, cyclin D1, p21 and p27 in MCF-7 cells Mol Cell Endocrinol 1998 142 57 65 10.1016/S0303-7207(98)00117-8 9783903
7. Goodwin PJ Ennis M Pritchard KI Koo J Hood N Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer J Clin Oncol 2009 27 3757 3763 10.1200/JCO.2008.20.0725 19451439
8. Yao S Kwan ML Ergas IJ Roh JM Cheng TD Hong CC Association of serum level of vitamin D at diagnosis with breast cancer survival: a case-cohort analysis in the pathways study JAMA Oncol 2017 3 351 357 10.1001/jamaoncol.2016.4188 27832250 PMC5473032
9. Rose AA Elser C Ennis M Goodwin PJ Blood levels of vitamin D and early stage breast cancer prognosis: a systematic review and meta-analysis Breast Cancer Res Treat 2013 141 331 339 10.1007/s10549-013-2713-9 24104883
10. Chlebowski RT Johnson KC Kooperberg C Pettinger M Wactawski-Wende J Rohan T Calcium plus vitamin D supplementation and the risk of breast cancer J Natl Cancer Inst 2008 100 1581 1591 10.1093/jnci/djn360 19001601 PMC2673920
11. Lohmann AE Chapman JA Burnell MJ Levine MN Tsvetkova E Pritchard KI Prognostic associations of 25 hydroxy vitamin D in NCIC CTG MA2.1, a phase III adjuvant randomized clinical trial of three chemotherapy regimens in high-risk breast cancer Breast Cancer Res Treat 2015 150 605 11 10.1007/s10549-015-3355-x 25833209
12. Robsahm TE Tretli S Torjesen PA Babigumira R Schwartz GG Serum 25-hydroxyvitamin D levels predict cancer survival: a prospective cohort with measurements prior to and at the time of cancer diagnosis Clin Epidemiol 2019 11 695 705 10.2147/CLEP.S207230 31496824 PMC6690592
13. Cortazar P Zhang L Untch M Mehta K Costantino JP Wolmark N Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis Lancet 2014 384 164 172 10.1016/S0140-6736(13)62422-8 24529560
14. Liedtke C Mazouni C Hess KR Andre F Tordai A Mejia JA Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer J Clin Oncol 2008 26 1275 1281 10.1200/JCO.2007.14.4147 18250347
15. Chiba A Raman R Thomas A Lamy PJ Viala M Pouderoux S Serum vitamin D levels affect pathologic complete response in patients undergoing neoadjuvant systemic therapy for operable breast cancer Clin Breast Cancer 2018 18 144 149 10.1016/j.clbc.2017.12.001 29290565 PMC6140343
16. Viala M Chiba A Thezenas S Delmond L Lamy PJ Mott SL Impact of vitamin D on pathological complete response and survival following neoadjuvant chemotherapy for breast cancer: a retrospective study BMC Cancer 2018 18 770 10.1186/s12885-018-4686-x 30060745 PMC6066931
17. Charehbili A Hamdy NA Smit VT Kessels L van Bochove A van Laarhoven HW Vitamin D (25 to 0H D3) status and pathological response to neoadjuvant chemotherapy in stage II/III breast cancer: data from the NEOZOTAC trial (BOOG 10 to 01) Breast 2016 25 69 74 10.1016/j.breast.2015.10.005 26614548
18. Clark AS Chen J Kapoor S Friedman C Mies C Esserman L Pretreatment vitamin D level and response to neoadjuvant chemotherapy in women with breast cancer on the I-SPY trial (CALGB 150007/150015/ACRIN6657) Cancer Med 2014 3 693 701 10.1002/cam4.235 24719175 PMC4101761
19. Kim JS Haule CC Kim JH Lim SM Yoon KH Kim JY Association between changes in serum 25-hydroxyvitamin D levels and survival in patients with breast cancer receiving neoadjuvant chemotherapy J Breast Cancer 2018 21 134 141 10.4048/jbc.2018.21.2.134 29963108 PMC6015976
20. Oh MG Han MA Park J Ryu SY Choi SW The prevalence of vitamin D deficiency among cancer survivors in a nationwide survey of the Korean population PLoS ONE 2015 10 e0129901 10.1371/journal.pone.0129901 26047013 PMC4457839
21. Ohta H Uenishi K Shiraki M Recent nutritional trends of calcium and vitamin D in East Asia Osteoporos Sarcopenia 2016 2 208 213 10.1016/j.afos.2016.08.002 30775488 PMC6372740
22. Wolff AC Hammond ME Hicks DG Dowsett M McShane LM Allison KH Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update J Clin Oncol 2013 31 3997 4013 10.1200/JCO.2013.50.9984 24101045
23. Kawase T Matsuo K Suzuki T Hirose K Hosono S Watanabe M Association between vitamin D and calcium intake and breast cancer risk according to menopausal status and receptor status in Japan Cancer Sci 2010 101 1234 1240 10.1111/j.1349-7006.2010.01496.x 20151981 PMC11159182
24. Park S Lee DH Jeon JY Ryu J Kim S Kim JY Serum 25-hydroxyvitamin D deficiency and increased risk of breast cancer among Korean women: a case-control study Breast Cancer Res Treat 2015 152 147 154 10.1007/s10549-015-3433-0 26037255
25. Thanasitthichai S Prasitthipayong A Boonmark K Purisa W Guayraksa K Negative impact of 25-hydroxyvitamin D deficiency on breast cancer survival Asian Pac J Cancer Prev 2019 20 3101 3106 10.31557/APJCP.2019.20.10.3101 31653160 PMC6982674
26. Shibata M Suzuki A Sekiya T Sekiguchi S Asano S Udagawa Y High prevalence of hypovitaminosis D in pregnant Japanese women with threatened premature delivery J Bone Miner Metab 2011 29 615 620 10.1007/s00774-011-0264-x 21384110
27. Shiraishi M Haruna M Matsuzaki M Murayama R Demographic and lifestyle factors associated with vitamin D status in pregnant Japanese women J Nutr Sci Vitaminol (Tokyo) 2014 60 420 428 10.3177/jnsv.60.420 25866306
28. Yoshimura N Muraki S Oka H Morita M Yamada H Tanaka S Profiles of vitamin D insufficiency and deficiency in Japanese men and women: association with biological, environmental, and nutritional factors and coexisting disorders: the ROAD study Osteoporos Int 2013 24 2775 2787 10.1007/s00198-013-2372-z 23673463
29. Tamaki J Iki M Sato Y Kajita E Nishino H Akiba T Total 25-hydroxyvitamin D levels predict fracture risk: results from the 15-year follow-up of the Japanese Population-based Osteoporosis (JPOS) Cohort Study Osteoporos Int 2017 28 1903 1913 10.1007/s00198-017-3967-6 28243705
30. Ohta H Kuroda T Tsugawa N Onoe Y Okano T Shiraki M Optimal vitamin D intake for preventing serum 25-hydroxyvitamin D insufficiency in young Japanese women J Bone Miner Metab 2018 36 620 625 10.1007/s00774-017-0879-7 29124437
Publication and source details

Original title: Impact of serum vitamin D on the response and prognosis in breast cancer patients treated with neoadjuvant chemotherapy

Eriko Tokunaga; Takanobu Masuda; Hideki Ijichi; Wakako Tajiri; Chinami Koga; Yumiko Koi; Yoshiaki Nakamura; Shinji Ohno; Kenichi Taguchi; Masahiro Okamoto

Breast Cancer (Tokyo, Japan) · 2021

© The Author(s) 2021https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T11:15:33.184795+00:00

DOI: 10.1007/s12282-021-01292-3 · PMC8732931